Catalyst Financial Partners’s AbbVie ABBV Stock Holding History

Catalyst Financial Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.87M	Sell	15,393 -939	-6%	-$202K	0.38%	39
2026 Q1	$3.55M	Buy	16,332 +2,099	+15%	+$466K	0.42%	36
2025 Q4	$3.25M	Buy	14,233 +785	+6%	+$179K	0.36%	35
2025 Q3	$3.11M	Buy	13,448 +267	+2%	+$54.4K	0.38%	34
2025 Q2	$2.45M	Sell	13,181 -155	-1%	-$28.8K	0.27%	38
2025 Q1	$2.79M	Buy	13,336 +504	+4%	+$98K	0.51%	30
2024 Q4	$2.28M	Buy	12,832 +363	+3%	+$66.7K	0.43%	32
2024 Q3	$2.46M	Buy	12,469 +173	+1%	+$32.3K	0.48%	31
2024 Q2	$2.11M	Buy	12,296 +1,078	+10%	+$179K	0.46%	32
2024 Q1	$1.84M	Buy	11,218 +316	+3%	+$54.5K	0.47%	31
2023 Q4	$1.69M	Buy	10,902 +296	+3%	+$43.2K	0.48%	34
2023 Q3	$1.58M	Buy	10,606 +1,767	+20%	+$259K	0.51%	32
2023 Q2	$1.19M	Sell	8,839 -440	-5%	-$64.5K	0.42%	34
2023 Q1	$1.48M	Buy	9,279 +635	+7%	+$97.1K	0.63%	27
2022 Q4	$1.4M	Buy	+8,644	New	+$1.33M	0.72%	27

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Catalyst Financial Partners's ABBV Position: Q2 2026 in Review

Catalyst Financial Partners reduced its AbbVie (ABBV) stake by 5.7% in Q2 2026, selling an estimated $202K and leaving 15,393 shares worth $3.87M. The position accounts for 0.38% of the portfolio, ranked #39.

Catalyst Financial Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Catalyst Financial Partners held 15,393 shares of AbbVie worth $3.87M as of Q2 2026.
Catalyst Financial Partners sold 939 AbbVie shares in Q2 2026, an estimated $202K.
AbbVie made up 0.38% of Catalyst Financial Partners's portfolio in Q2 2026, its #39 holding.
Catalyst Financial Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Catalyst Financial Partners's 13F filing for Q2 2026, filed 30 Jul 2026.